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ABSTRACT
Allogeneic hematopoietic stem cell transplantation (SCT) has the potential to cure patients with acute
leukemia or myelodysplastic syndromes (MDS), but a number of prognostic factors can influence the outcome
of transplantation. At present, no transplantation-specific risk score exists for this patient population. We
propose a simple scoring system for patients with acute myelogenous leukemia (AML), acute lymphoblastic
leukemia (ALL), or MDS, based on a retrospective analysis of 445 patients undergoing SCT at our institution
(divided into training and validation subsets). The score depends on 5 variables: age, disease, stage at
transplantation, cytogenetics, and pretransplantation ferritin. It divides patients into 3 groups of comparable
size, with 5-year overall survival (OS) of 56% (low risk), 22% (intermediate risk), and 5% (high risk). This
prognostic score could be useful in making treatment decisions for individual patients, in stratifying patients
entering clinical trials, and in adjusting transplantation outcomes across centers under the new federal
reporting rules.
© 2008 American Society for Blood and Marrow Transplantation
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Allogeneic hematopoietic stem cell transplanta-
tion (SCT) can be curative for patients with acute
myelogenous leukemia (AML) [1], acute lymphoblas-
tic leukemia (ALL) [2], or myelodysplastic syndromes
(MDS) [3]. However, there is considerable heteroge-
neity in transplantation outcomes within this group of
patients, with many patient-related, disease-related,
and transplant-related factors inﬂuencing prognosis. A
prognostic score that is speciﬁcally applicable to this
patient population would be useful in several ways:
ﬁrst, it would help with prognostication at the time of
transplantation consideration, which could have an
impact on treatment decisions; second, it would allow
stratiﬁcation of patients entering clinical trials of
transplantation. Successful prognostic scores devel-
oped for other diseases, such as the International28Prognostic Index for patients with aggressive non-
Hodgkin lymphoma (NHL) [4] or the International
Prognostic Scoring System (IPSS) for patients with
MDS [5], have been tremendously useful to clinicians
and researchers alike for prognostication and clinical
trial stratiﬁcation. Unfortunately, there are at present
few prognostic scores designed speciﬁcally for patients
undergoing SCT. Three general risk scores have been
proposed that are applicable to all patients undergoing
transplantation [6-8]; however, by design, those scores
rely minimally if at all on disease-speciﬁc factors (such
as cytogenetics). The European Group for Blood and
Marrow Transplantation (EBMT) developed a risk
score for patients with chronic myelogenous leukemia
(CML) [9]. No such score currently exists speciﬁcally
for patients with acute leukemia or MDS undergoing
SCT, despite the fact that they account for a substan-
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allogeneic transplants reported from the International
Bone Marrow Transplant Registry to the Center for
International Blood and Marrow Transplant Research
(CIBMTR) [10]). Although the IPSS has prognostic
values for patients with MDS undergoing transplan-
tation [11,12], this score was derived on a cohort of
patients who were not transplanted, and thus may not
be an optimal prognostication tool in the context of
SCT.
There is yet another beneﬁt to transplant-speciﬁc
prognostic scores. In December 2005, the U.S. Stem
Cell Therapeutic and Research Act of 2005 created
the C.W. Bill Young Cell Transplantation Program.
As part of this program, U.S. centers will be required
to report outcomes data for all allogeneic transplan-
tation, and this data will be publicly available. It will
therefore be critical to have well-deﬁned risk stratiﬁ-
cation tools to allow calibration of outcomes across
centers that may transplant patients with different risk
proﬁles.
In this study, we propose and validate a simple
prognostic score for patients with AML, ALL, or
MDS undergoing SCT, based on the outcomes of 445
patients transplanted at our institution.
METHODS
Patients
We studied 660 consecutive adult patients with
AML, ALL, or MDS who underwent allogeneic stem
cell transplantation at the Dana-Farber/Brigham and
Women’s Hospital transplant program between Jan-
uary 1997 and December 2005. Patients with therapy-
related AML or AML arising out of MDS were in-
cluded. Patients with CMML were excluded. The
following pretransplantation variables were collected:
age, sex, disease type and stage, prior leukemogenic
therapy, cytogenetics, donor HLA match, stem cell
source, conditioning regimen, graft-versus-host dis-
ease (GVHD) prophylaxis regimen, cytomegalovirus
(CMV) serostatus of donor and recipient, sex of do-
nor, and pretransplantation serum ferritin [13]. Fer-
ritin was included because we have recently demon-
strated that it has an important prognostic impact for
patients with MDS or acute leukemia receiving my-
eloablative conditioning [13]. For patients receiving
reduced intensity conditioning (RIC), ferritin was not
included as a prognostic factor in the multivariable
models. Patients with missing data were excluded; this
left 445 patients, who form the basis of this study.
Institutional review board (IRB) approval was ob-
tained from the Ofﬁce for the Protection of Research
Subjects (OPRS) at Dana-Farber/Harvard Cancer
Center, in accordance with the principles of the Dec-
laration of Helsinki.Cytogenetics
Cytogenetics were determined by standard meta-
phase karyotype analysis or ﬂuorescence in situ hy-
bridization (FISH; without requiring central review).
For ALL, t(9;22) and t(4;11) are considered adverse,
and all others intermediate. We used the MRC clas-
siﬁcation scheme for AML [14], and the cytogenetic
classiﬁcation scheme of the IPSS for MDS [5]. For
risk group assignment purposes, we used the cytoge-
netics at diagnosis for patients in remission, and the
pretransplantation cytogenetics for patients with ac-
tive disease.
Transplantation
Patients were transplanted under several treat-
ment and investigational protocols over the 9-year
period covered by this study. Myeloablative condi-
tioning regimens consisted mostly of cyclophospha-
mide (3600 mg/m2 or 120 mg/kg) plus either total
body irradiation (TBI) (1400 cGy in 7 fractions) or
busulfan (16 mg/kg by mouth or 12.8 mg/kg i.v.).
Reduced intensity regimens consisted mostly of ﬂu-
darabine (120 mg/m2) with busulfan (3.2 mg/kg). Pa-
tients received either bone marrow or peripheral
blood stem cells, from matched or mismatched, re-
lated or unrelated donors. Thirteen patients received
umbilical cord blood (UCB) transplants. GVHD pro-
phylaxis regimens consisted mostly of a combination
of calcineurin inhibitor and methotrexate (MTX), ta-
crolimus plus sirolimus, with or without low-dose
methotrexate, or T cell depletion (TCD).
Statistics
Patient baseline characteristics were reported de-
scriptively. Overall survival (OS) and disease-free sur-
vival (DFS) were calculated using the Kaplan-Meier
method. OS was deﬁned as the time from stem cell
infusion to death from any cause. Patients who were
alive or lost to follow-up were censored at the time last
seen alive. DFS was deﬁned as the time from stem cell
infusion to relapse or death from any cause, whichever
occurred ﬁrst. Patients who were alive without relapse
were censored at the time last seen alive and relapse-
free. The log-rank test was used for comparisons of
Kaplan-Meier curves. Cumulative incidence curves
for nonrelapse death and relapse with or without
death were constructed reﬂecting time to relapse and
time to nonrelapse death as competing risks. The
difference between cumulative incidence curves in the
presence of a competing risk was tested using the Gray
method [15]. Time to relapse and time to nonrelapse
death were measured from the date of stem cell infusion.
The entire cohort was split randomly 2:1 into a
training set (n  297) and a validation set (n  148).
Potential prognostic factors for survival were exam-
ined in the proportional hazards model, as were rele-
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sumption was tested for all important variables both
graphically and analytically [16]. Regression assump-
tions were tested using Martingale and deviance re-
sidual analysis. Transformation for continuous vari-
ables to categoric variables was done by visual analysis
of residual plots. A parsimonious model was built
using a stepwise variable selection method, with an
entry criterion of P  .1 and a retention criterion of
P  .05. To create the risk score, each variable was
assigned an integral number of points based roughly
on its associated hazard ratio (HR) from the Cox
model, as described in the text. We calculated the
c-statistic for the validation cohort [17], deﬁned as the
proportion of informative patient pairs whose out-
comes are correctly ordered by the risk score. All
calculations were done using SAS 9.1 (SAS Institute
Inc, Cary, NC), R (version 2.3.1), Splus (version 3.4),
and Matlab 6.5 (Mathworks, Natick, MA).
RESULTS
Patient Characteristics
We retrospectively reviewed the posttransplanta-
tion outcomes of 445 adult patients with AML, ALL,
or MDS transplanted at our institution between 1997
and 2005. Median follow-up for survivors was 25
months (range: 6-102). Table 1 lists the baseline char-
acteristics of those patients. The median age in this
cohort was 45 years (range: 18-71). Forty-three per-
cent of patients had AML, 18% had ALL, and 39%
had MDS (including 18% with secondary AML).
Twelve percent of patients had therapy-related dis-
ease. Forty-eight percent of patients were trans-
planted in ﬁrst complete remission (CR1) or with
untreated MDS, whereas 33% had active disease at
the time of transplantation. Sixty-nine percent had
myeloablative conditioning (mostly cyclophospha-
mide  TBI), whereas 31% had nonmyeloablative
conditioning (mostly low-dose busulfan  ﬂudara-
bine); 41% of patients received a graft from an HLA-
matched sibling; 61% received peripheral blood stem
cells (PBSC), whereas 36% received bone marrow and
3% received cord blood.
Cytogenetics was available for all 445 patients.
AML and MDS cytogenetics were classiﬁed according
to the MRC [14] and IPSS [5] grouping schemes,
respectively. For ALL, we considered t(9;22) and t(4;11)
to be adverse, and all others to be intermediate. When
classiﬁed in this way, 47% of the patients had inter-
mediate cytogenetics, 23% had favorable cytogenetics,
and 30% had adverse cytogenetics.
Outcomes and Prognostic Factors
For the entire cohort, the 5-year OS was 32%, and
the 5-year DFS was 31%; the 5-year cumulative inci-Table 1. Baseline Characteristics of the Patients
Variable Total, No. (%)*
Number of patients analyzed 445 (100%)
Median age in years (range) 45 (18-71)
Disease
ALL 80 (18)
AML 191 (43)
MDS 174 (39)
RA/RARS/RCMD 79 (18)
RAEB 17 (4)
AML from MDS 78 (18)
Therapy-related disease 54 (12)
Stage
Untreated MDS 86 (19)
Untreated AML/ALL 10 (2)
CR1 131 (29)
CR > 2 74 (17)
Induction failure 75 (17)
Active relapse 69 (16)
Cytogenetics†
Favorable 102 (23)
Intermediate 210 (47)
AML/MDS adverse 101 (23)
ALL adverse 32 (7)
Graft source
Peripheral blood 271 (61)
Bone marrow 161 (36)
Cord blood 13 (3)
Donor HLA match
MRD 184 (41)
MUD 193 (43)
Mismatched related 9 (2)
Mismatched unrelated 59 (13)
Conditioning
Myeloablative 309 (69)
Cy/TBI 297 (67)
Bu/Cy 9 (2)
Other 3 (0)
Reduced intensity 136 (31)
Bu/flu 127 (29)
Other 9 (2)
GVHD prophylaxis
CnI  steroids  MMF 50 (11)
CnI  MTX  steroids 172 (39)
CnI  Siro  MTX 165 (37)
TCD 58 (13)
Sex‡
Female -> Male 98 (22)
Male -> Female 112 (25)
Male -> Male 137 (31)
Female -> Female 95 (21)
CMV seropositivity
Recipient 182 (41)
Donor 164 (37)
ALL indicates acute lymphoblastic leukemia; AML, acute myelog-
enous leukemia; MDS, myelodysplastic syndrome; RA, refrac-
tory anemia; RARS, refractory anemia with ringed sideroblasts;
RCMD, refractory cytopenia with multilineage dysplasia;
RAEB, refractory anemia with excess blasts; CR, complete re-
mission; MRD, matched related donor; MUD, matched unre-
lated donor; Cy, cyclophosphamide; TBI, total body irradiation;
Bu, Busulfan; ﬂu, ﬂudarabine; GVHD, graft-versus-host disease;
CnI, calcineurin inhibitor (cyclosporine or tacrolimus); MMF,
mycophenolate mofetil; MTX, methotrexate; Siro, Sirolimus;
TCD, T cell depletion; CMV, cytomegalovirus.
*Percentages may not add to 100 because of rounding.
†See Methods section for details.
‡Donor sex information was missing for 3 patients.
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mulative incidence of nonrelapse mortality (NRM)
was 27%. We divided the patients 2:1 by random
assignment into a training set and a validation set. All
subsequent analyses to establish the risk score were
performed on the group of patients in the training set
(n  297). Within this group, we performed propor-
tional hazards univariate and multivariate analyses to
determine the prognostic factors for OS. All the vari-
ables from Table 1 were included in the model. We also
included pretransplantation serum ferritin for patients
receiving myeloablative conditioning (as this is the pa-
tient subgroup for which ferritin has a signiﬁcant prog-
nostic impact [13]) in the model, as well as year of
transplantation. The results are shown in Table 2. Thevariables that had a signiﬁcant impact on OS in multi-
variate analysis were: age, disease, stage at transplanta-
tion, cytogenetics, pretransplantation ferritin (for pa-
tients undergoing myeloablative transplantation), and
year of transplantation. We also built a parsimonious
model using stepwise variable selection; in this analysis,
the same 5 variables were selected (data not shown).
Donor HLA match, conditioning regimen intensity,
graft source, GVHD prophylaxis regimen, sex mis-
match, CMV serostatus, and therapy-related disease
were not signiﬁcant in this model.We also examined the
effect of pretransplantation Eastern Cooperative Oncol-
ogy Group (ECOG) performance status on outcome.
This data was available for 32% of the patients in this
study, with a median value of 0 (range: 0-3). Perfor-Table 2. Univariate and Multivariate Analyses for Overall Survival
Univariate Analysis Multivariate Analysis
Variable HR P HR P
Age >40 1.4 .036 2.0 .0007
Disease
AML 1.0 ref 1.0 ref
ALL 1.0 1.0 1.0 .9
Low-risk MDS* 0.8 .4 1.0 1.0
High-risk MDS* 2.4 .040 3.1 .023
AML arising from MDS 1.6 .034 1.6 .071
Therapy-related disease 1.4 .2 1.2 .7
Cytogenetics
Favorable 0.8 .2 0.6 .037
Intermediate 1.0 ref 1.0 ref
Adverse ALL 1.1 .8 1.3 .4
Adverse AML/MDS 1.8 .002 1.6 .051
Stage
CR1/Unt MDS 1.0 ref 1.0 ref
CR >1 1.0 .9 1.5 .2
Untreated AML/ALL 1.9 .2 2.1 .2
Induction failure 2.2 <.0001 2.2 .0007
Relapse 2.0 .003 2.6 .0001
Ferritin >2500† 1.4 .067 1.5 .043
Graft source
Bone marrow 1.0 ref 1.0 ref
Peripheral blood‡ 1.0 .8 1.2 .4
Donor match
MRD 1.0 ref 1.0 ref
Non-MRD 1.0 .9 1.1 .8
Conditioning regimen
Ablative 1.0 ref 1.0 ref
Reduced intensity 1.1 .5 1.0 .9
GVHD prophylaxis
CnI  MTX  MMF 1.0 ref 1.0 ref
CnI  Siro  MTX 0.7 .055 0.8 .4
TCD 0.7 .2 0.9 .6
Gender mismatch 1.2 .3 1.1 .7
Donor CMV seropositive 1.2 .2 1.1 .5
Recipient seropositive 1.0 .9 1.0 .9
Year of transplantation
1997-2000 1.0 ref 1.0 ref
2001-2005 0.7 .081 0.6 .034
HR indicates hazard ratio; ref, reference group; Unt MDS, untreated MDS; other abbreviations are described in Table 1.
*Low-risk MDS was deﬁned as RA, RARS, and RCMD; high-risk as RAEB-1 and RAEB-2.
†For patients receiving myeloablative conditioning (see text).
‡Including umbilical cord blood recipients.
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tation outcome (HR for mortality 1.3, P  .2).
Results were similar if we grouped cytogenetics
according to our recently proposed grouping scheme
[18]. The model ﬁt was slightly stronger (Akaike’s
information criterion (AIC) 1685 versus 1735, with a
lower score indicating a better model ﬁt), but the
conclusions were unaltered. We also reclassiﬁed ALL
cytogenetics according to the results of the MRC
UKALLXII/ECOG 2993 study [19]; this had no sub-
stantial effect on the model ﬁt (AIC 1735).
Derivation of the Prognostic Score
For each of the signiﬁcant variables in the multi-
variate analyses above, we created categoric variables
using proportional hazards model or visual analysis of
Martingale/deviance residuals against each continuous
predictor. The results (not shown) allowed us to cat-
egorize age into 2 groups (40 versus 40); disease
type into 2 groups (low-risk MDS, AML, or ALL,
versus high-risk MDS or MDS transformed to AML);
stage into 3 groups (AML/ALL in CR1 or untreated
MDS, versus CR  1 or induction failure, versus
active relapse or untreated leukemia); cytogenetics
into 3 groups (favorable versus intermediate versus
adverse); and pretransplantation ferritin into 2 groups
(myeloablative conditioning and ferritin 2500 ng/
dL, versus RIC or ferritin 2500 ng/dL). The result-
ing multivariat model using those categoric variables
is shown in Table 3. The results were essentially
identical when using an ALL cytogenetics classiﬁca-
tion based on the MRC/ECOG ALL study [19] (not
shown).
We then created a risk score by assigning each
variable a number of points. We strove for a simple
risk score that could be calculated easily during a
Table 3. Final Multivariable Model for Overall Survival
Variable HR P
Age
<40 1.0 ref
>40 1.8 .001
Disease
Low-risk MDS/AML/ALL 1.0 ref
High-risk MDS/transformed MDS 2.0 .0005
Cytogenetics
Favorable 1.0 ref
Intermediate 1.7 .014
Adverse 3.2 <.0001
Stage
CR1 or untreated MDS 1.0 ref
CR >1 or Induction failure 1.8 .001
AML/ALL untreated or active relapse 2.4 <.0001
Ferritin
RIC OR ferritin <2500 1.0 ref
Ablative AND ferritin >2500 1.7 .007
RIC indicates reduced-intensity conditioning; other abbreviations
are as described in Tables 1 and 2.clinical encounter. Therefore, we chose integer values
for the points, and assigned them based on the HR in
the proportional hazards model from Table 3. To
variables with HR between 1.5 and 2.0, we assigned a
score of 1; and to those with HR above 2.0, we as-
signed a score of 2. The scoring system thus obtained
is described in Table 4. Each variable is assigned a
score; the sum of the individual components is the
overall prognostic score. This deﬁnes 3 risk catego-
ries, low (score 2), intermediate (score  3), and
high (score 4). The OS of the 297 patients in the
training set, stratiﬁed according to their prognostic
score, is plotted in Figure 1A.
Validation of the Risk Score
We calculated the risk score for the 148 patients in
the validation set, whose outcomes were not used for
the derivation of the score. Their OS is shown in
Figure 1B. The prognostic score remained a highly
statistically signiﬁcant in this group (log-rank P 
.0001). We also calculated the c-statistic in the valida-
tion cohort. This statistic indicates how often infor-
mative pairs of patients are correctly ordered by the
risk score with regard to their survival. A score of 1.0
indicates perfect agreement with the data. For the
validation group, using time of death as a continuous
variable, the c-statistic was 0.66 (for comparison, in
Table 4. Calculation of the Prognostic Score
Variable Score
Age
<40 0
>40 1
Disease
Low-risk MDS,* AML, or ALL 0
High-risk MDS* or transformed MDS 1
Cytogenetics†
Favorable 0
Intermediate 1
Adverse 2
Stage
CR1 or untreated MDS 0
CR >1 or induction failure 1
AML/ALL untreated or active relapse 2
Ferritin
RIC OR ferritin <2500 ng/dL 0
Ablative AND ferritin >2500 ng/dL 1
Final score‡ Risk group
<2 Low
3 Intermediate
>4 High
*Low-risk MDS is deﬁned as RA, RARS, or RCMD; high-risk
MDS is deﬁned as RAEB.
†For ALL, t(9;22) and t(4;11) are considered adverse, and all others
intermediate. AML cytogenetics are grouped according to the
MRC classiﬁcation scheme, and MDS cytogenetics according to
the IPSS scheme.
‡This is calculated as the sum of the individual components.
Abbreviations are as described in Tables 1 to 3.
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study the corresponding c-statistic was 0.626). If we
considered the binary outcome of survival to 2 years
(as in the Pretransplantation Assessment of Mortality
[PAM] score of Parimon and colleagues [8]), the c-
statistic was 0.79 (for comparison, it was 0.72-0.76 in
the PAM study [8]).
Outcomes by Risk Group
We calculated the prognostic score for all 445
patients (including both those in the training and
those in the validation set). As shown in Table 5, the
patients are thus divided into 3 groups of comparable
size (each comprising between 28% and 41% of pa-
tients). Figure 2 shows the outcomes of all patients
stratiﬁed by their risk score. OS is shown in Figure 2A,
and DFS in Figure 2B. The 5-year values for OS,
DFS, cumulative CIR, and NRM for each risk group
are given in Table 5.
DISCUSSION
We have created a new prognostic score for pa-
tients with acute leukemia or MDS undergoing allo-
geneic stem cell transplantation (SCT). This score
depends on only 5 patient and disease characteristics:
age, disease, stage at transplantation, cytogenetics, and
pretransplantation serum ferritin (for patients under-
going myeloablative transplantation). By combining
these 5 variables, our scoring system stratiﬁes patients
into 3 groups of roughly comparable size at very
different risk of death after transplantation (with
5-year OS ranging from 56% in the low-risk group to
5% in the high-risk group), through an effect on bothrelapse and NRM. This scoring system was based on
retrospective transplantation results at a single insti-
tution. Nonetheless, it retained its high prognostic
signiﬁcance when applied to a validation set of ran-
domly selected patients who were not included in the
derivation of the score (see Figure 1B). The c-statistic,
which quantiﬁes the agreement of the prognostic
score with the outcome of interest (here, OS) was at
least as high as that of other prognostic scores [6,8],
which were not designed speciﬁcally for patients with
acute leukemia or MDS. In its current form, this
scoring system does not include pretransplantation
comorbidity score, which was not available in our
cohort but could be incorporated in future versions. It
must also be noted that many of the patients included
in this study were part of the cohorts used in our
previous work on the prognostic impact of cytogenet-
ics and ferritin levels [13,18]. However, the intent of
the present study is not to validate our prior results,
but to integrate them into a more versatile scoring
system.
All of the variables included in this score have
been previously shown to have a prognostic impact
after transplantation. Age is often considered an ad-
verse prognostic factor through an increase in NRM
[20,21] (although at least 2 retrospective multicenter
studies failed to document a signiﬁcant effect on OS
[22,23]). The possibility of a superior outcome for
low-risk MDS compared to high-risk MDS has been
previously suggested [24,25]. More advanced disease
stage is always associated with worse outcome (as
demonstrated, eg, by the data of the CIBMTR). Pre-
transplantation serum ferritin has also been shown to
carry prognostic signiﬁcance for patients undergoingTable 5. Summary of Outcomes in the Entire Cohort By Risk Group
Risk Group % of pts 5-y OS 5-y DFS 5-y CIR 5-y NRM
Low 41% 56% (48-64) 51% (43-59) 25% (18-32) 24% (17-30)
Intermediate 31% 22% (10-33) 22% (12-32) 53% (42-65) 25% (17-32)
High 28% 5% (0-12) 6% (0-12) 58% (48-67) 36% (26-47)
Numbers in parentheses are 95% conﬁdence intervals.
OS indicates overall survival; DFS, disease-free survival; CIR, cumulative incidence of relapse; NRM, non-relapse mortality. Risk groups are
deﬁned in Table 4.
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[13,26]. Finally, the prognostic importance of cytoge-
netics has been conﬁrmed in several studies [27-31],
including our own, where we demonstrated that cyto-
genetics inﬂuenced the risk of relapse, and proposed a
transplantation-speciﬁc cytogenetics grouping scheme
[18]. Although our grouping scheme allowed a better
model ﬁt to the data, it was derived on a cohort that
included most of the patients in the current study.
Because we have not yet validated our grouping
scheme in a multi-institution study, we did not use it
for the present risk score. In the future, the recogni-
tion of prognostic subtypes based on molecular anal-
yses within the normal karyotype category will un-
doubtedly alter the scheme [32] and subdivide this
category, which still includes the majority of patients.
This scoring system could be used in several ways.
First, it should allow clinicians to easily estimate the
prognosis of patients with MDS or acute leukemia
who are candidates for SCT. This could be helpful in
discussing the value of transplantation and in choosing
a treatment course. It also identiﬁes a subgroup of
patients (high-risk) with a dismal prognosis (5-year
OS of 5%), for whom the value of transplantation may
be questionable, and who may especially beneﬁt from
enrollment into clinical trials. Second, this scoring
system could be used to stratify patients entering clin-
ical trials of transplantation. At present, there is no
consensus as to how to perform such stratiﬁcation, and
some variables that are commonly used, such as donor
HLA match, may not be nearly as prognostically im-
portant today as less commonly used variables (such as
cytogenetics). Similar prognostic scores, such as the
IPI for aggressive lymphoma and the IPSS for MDS,
are widely used in clinical trial design. Finally, our
prognostic score could be used under the new federal
reporting requirements for transplant centers to adjust
for differences in patient mix and allow a fairer com-
parison of outcomes across centers.
Prospective validation of this scoring system
through a multicenter collaboration would conﬁrm its
utility and possibly ﬁne-tune the score assignments.
Further in the future, it is possible that improvements
in the care of speciﬁc patient subgroups (eg, chelationof iron-overloaded patients, or the use of tyrosine
kinase inhibitors after transplantation for Ph ALL)
would require reevaluation of the scoring scheme.
This reevaluation could be accomplished through a pe-
riodic reexamination of multicenter transplantation data,
such as those that will be reported to the Stem Cell
Therapeutic Outcome Database, which the CIBMTR
will administer. This process could even be semiauto-
mated such that clinicians worldwide would have
ready access to up-to-date, international prognostic
scoring systems for patients with a variety of diseases
undergoing SCT.
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